Cas:565-50-4 trans-terpin manufacturer & supplier

Chemical Name:trans-terpin

CAS.NO:565-50-4

Synonyms:(r-1,t-4)-p-menthane-1,8-diol;cis-p-menthane-1,8-diol;trans-1,8-terpin;4-(2-hydroxyisopropyl)-1-methylcyclohexanol;P-MENTHANE-1,8-DIOL;TRANS-4-(2-HYDROXYISOPROPYL)-1-METHYLCYCLOHEXANOL;trans-terpinterpene;trans-p-menthane-1,8-diol;standardforgc;4-(2-Hydroxyisopropyl)-1-methylcyclohexanol,p-Menthane-1,8-diol;(+)-cis-p-menth-2-ene-1,8-diol;4-(2-hydroxypropan-2-yl)-1-methylcyclohexanol

Molecular Formula:C₁₀H₂₀O₂

Molecular Weight:172.26500

HS Code:

Physical and Chemical Properties:

Melting point:115-118ºC (dec.)

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:40.46000

Exact Mass:172.14600

LogP:1.69850

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like (r-1,t-4)-p-menthane-1,8-diol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(2-hydroxypropan-2-yl)-1-methylcyclohexanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,trans-1,8-terpin Use and application,trans-1,8-terpin technical grade,usp/ep/jp grade.

Related News: Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. trans-terpin manufacturer The FDA also said that the labeling of the diagnostic, which comes in different versions, included performance claims that did not match up with results seen in clinical studies—and that the data Innova submitted for review “was identical to data previously provided by other manufacturers” in separate requests for emergency COVID authorizations, raising additional questions. trans-terpin supplier Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. trans-terpin vendor The FDA also said that the labeling of the diagnostic, which comes in different versions, included performance claims that did not match up with results seen in clinical studies—and that the data Innova submitted for review “was identical to data previously provided by other manufacturers” in separate requests for emergency COVID authorizations, raising additional questions. trans-terpin factory A 40-year-old Chinese woman also tested positive. She was already in quarantine as she is related to another patient who contracted the virus.